Eliglustat
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Eliglustat
Eliglustat: Known uses and market status in Canada
Summary
The TxGNN model has no candidate with a score of 0.99 or higher for Eliglustat, so there is currently no new predicted indication. The drug’s recorded uses are listed below. These are the drug’s own recorded uses, not model candidates.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (no model candidate scored 0.99 or higher) |
| Known uses recorded for this drug | 1 |
| Evidence level | Not applicable |
| Canada Market Status | Marketed (marketed DINs: 1 of 1) |
| Number of DINs | 1 (marketed: 1) |
Known uses recorded for this drug
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| gaucher disease | licence in another country |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| none |
Canada Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 02463261 | CERDELGA | Valid |
Safety Considerations
Drug Interactions: The compiled data lists 100 potential interactions (the first 20 are shown in the data). Examples of Major interactions:
- Abiraterone
- Fosamprenavir
- Fosaprepitant
- Fosphenytoin
Examples of Moderate interactions include paclitaxel, chlorpheniramine, codeine, tramadol, ranitidine, nifedipine, afatinib, ethinylestradiol, fluvoxamine, fostamatinib, galantamine, gilteritinib, aliskiren, alprazolam, ambrisentan and abametapir (topical).
Eliglustat is also noted to be a substrate of P-gp and CYP2D6/3A4, which complicates dosing and co-medication.
For warnings and contraindications, please refer to the package insert.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.